CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.
Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肠道微生物群是栖息在人类肠道中的厌氧菌和兼性需氧菌组成的大型共生群落,其活动显著影响人类健康。越来越多的证据表明,肠道微生物组在肿瘤相关免疫调节中发挥重要作用。在肿瘤微环境(TME)中,肠道微生物组及其代谢产物影响免疫细胞的分化和功能,从而调控肿瘤的免疫逃逸。肠道微生物组可间接影响个体对多种经典肿瘤免疫疗法的反应,包括免疫检查点抑制剂治疗和过继性免疫治疗。通过抗生素、益生元和粪菌移植(FMT)进行微生物调控,可优化肠道微生物组的组成,提高免疫治疗的疗效,为肿瘤治疗带来新的视角和希望。
The gut microbiota is a large symbiotic community of anaerobic and facultative aerobic bacteria inhabiting the human intestinal tract, and its activities significantly affect human health. Increasing evidence has suggested that the gut microbiome plays an important role in tumor-related immune regulation. In the tumor microenvironment (TME), the gut microbiome and its metabolites affect the differentiation and function of immune cells regulating the immune evasion of tumors.
The gut microbiome can indirectly influence individual responses to various classical tumor immunotherapies, including immune checkpoint inhibitor therapy and adoptive immunotherapy. Microbial regulation through antibiotics, prebiotics, and fecal microbiota transplantation (FMT) optimize the composition of the gut microbiome, improving the efficacy of immunotherapy and bringing a new perspective and hope for tumor treatment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。